neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.
Company profile
Ticker
NRBO
Exchange
Website
CEO
Jeong Gu Kang
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Gemphire Therapeutics Inc.
SEC CIK
Corporate docs
Subsidiaries
NeuroBo Therapeutics, Inc. • NeuroBo Co., Ltd. • ANA Therapeutics, LLC ...
NRBO stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
25 Jul 24
424B3
Prospectus supplement
24 Jul 24
S-1
IPO registration
18 Jul 24
8-K
Regulation FD Disclosure
16 Jul 24
D
$17.00 mm in equity / options / securities to be acquired, sold $17.00 mm, 2 investors
1 Jul 24
8-K
Other Events
26 Jun 24
424B5
Prospectus supplement for primary offering
25 Jun 24
8-K
Entry into a Material Definitive Agreement
25 Jun 24
8-K
Lipid-Lowering Effect of DA-1726 Shown to be Superior Compared to Tirzepatide
24 Jun 24
8-K
Departure of Directors or Certain Officers
7 Jun 24
Latest ownership filings
4/A
Change in insider ownership (amended)
10 Jul 24
4
Change in insider ownership
25 Jun 24
SC 13D/A
DONG-A ST CO., LTD
25 Jun 24
4
Michael Salsbury
7 Jun 24
4
JASON L GROVES
7 Jun 24
4
ANDREW I KOVEN
7 Jun 24
4
Mark A Glickman
7 Jun 24
4
D GORDON STRICKLAND
7 Jun 24
4
James Patrick Tursi
7 Jun 24
4
Marshall H Woodworth
4 Mar 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.99 mm | 15.99 mm | 15.99 mm | 15.99 mm | 15.99 mm | 15.99 mm |
Cash burn (monthly) | 2.15 mm | 1.24 mm | 2.29 mm | 1.69 mm | 2.15 mm | 1.22 mm |
Cash used (since last report) | 8.31 mm | 4.78 mm | 8.87 mm | 6.52 mm | 8.30 mm | 4.73 mm |
Cash remaining | 7.68 mm | 11.21 mm | 7.12 mm | 9.46 mm | 7.68 mm | 11.25 mm |
Runway (months of cash) | 3.6 | 9.1 | 3.1 | 5.6 | 3.6 | 9.2 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 18.79 mm |
Total shares | 18.45 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Dong-a ST | 12.43 mm | $16.03 mm |
E&Investment | 6.02 mm | $2.74 mm |
BNP Paribas Arbitrage | 4.00 | $16.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jun 24 | Dong-a ST | Common Stock | Buy | Acquire P | No | No | 3.93 | 2,544,530 | 10.00 mm | 5,348,229 |
7 Jun 24 | Tursi James Patrick | Common Stock | Grant | Acquire A | No | No | 0 | 5,051 | 0.00 | 9,072 |
7 Jun 24 | Koven Andrew I | Common Stock | Grant | Acquire A | No | No | 0 | 5,051 | 0.00 | 17,552 |
7 Jun 24 | Mark A Glickman | Common Stock | Grant | Acquire A | No | No | 0 | 5,051 | 0.00 | 9,740 |
News
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
22 May 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
22 May 24
NeuroBo Pharmaceuticals Q1 2024 GAAP EPS $(1.32) Misses $(1.10) Estimate
9 May 24
Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals with Buy Rating, Announces Price Target of $10
8 May 24
NeuroBo To Present Latest Pre-Clinical Data On Cardiometabolic Assets, DA-1241 And DA-1726, Targeting MASH And Obesity, At Scientific Conferences In June
30 Apr 24
Press releases
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
11 Jul 24
NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
22 May 24
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
9 May 24